Page 1,022«..1020..1,0211,0221,0231,024..1,0301,040..»

Category Archives: Transhuman News

Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research – BioSpace

Posted: March 26, 2021 at 6:26 pm

The two companies will launch in Korea Ocean Genomics advanced AI-based transcriptome analysis and biomarker platform (txome.ai) as both a cloud-based and on-premises solution. Geninus will leverage the txome.ai platform to expand its CancerSCAN clinical diagnostics platform for its hospital customers, and for biomarker discovery services with academic and biotechnology clients. Ocean Genomics and Geninus will also partner on the co-development of a series of RNA-informed multidimensional biomarkers for research and clinical use.

We are excited to embark on this partnership with Geninus said Carl Kingsford, co-founder and CEO, Ocean Genomics. Ocean Genomics expertise in AI and computational method development, together with Geninus translational experts and access to data is a powerful combination. Working together, we can advance the field and enhance the uses of RNA biomarkers in clinical and research applications and provide essential insights for clinicians who care for cancer patients.

Dr. Woong Yang Park, CEO, Geninus, said, Genome analysis for precision cancer medicine is becoming an essential process in hospitals. Gene expression analysis on tumor tissue RNA can deliver critical information for targeted therapy and immunotherapy. We expect to advance precision medicine by incorporating Ocean Genomics txome.ai into Geninus clinical diagnostics platform, CancerSCAN. We look forward to working with Ocean Genomics in co-developing biomarkers and expanding services to our academic and biotechnology customers.

About Ocean Genomics, Inc.

Ocean Genomics mission is to enable drug development and personalized medicine by combining AI with advanced gene-expression analysis to determine rich gene expression signatures and develop RNA-informed multidimensional biomarkers. DNA is a predictor of what might happen in the future, while RNA reveals whats happening now, making it an essential component in drug development, screening and monitoring, diagnosis and treatment selection. Analyzing RNA requires far more advanced software and computational methods than analyzing DNA.

Ocean Genomics provides the required specialized expertise in AI and transcriptomic analysis and advanced computational software solutions required to power discovery and development programs with life sciences companies and academic researchers. Ocean Genomics provides a self-service, fully configured, cloud-based platform, txome.ai, which provides advanced transcriptome analysis and biomarker generation.

For more information, please visit oceangenomics.com and connect with us on Twitter, and LinkedIn.

About Geninus Inc.

Geninus provides clinical genome analysis solutions for precision medicine clinics. CancerSCAN, a cancer genome diagnostics platform, is used to inform personalized cancer treatment with targeted therapeutics and immunotherapy in major hospitals in Korea and Japan. CancerSCAN includes an information management system, a bioinformatics pipeline, variant annotation, clinical reports, and datacenter. OncoSTATION, a user interface for CancerSCAN, can be installed within hospital information systems. In addition, Geninus operates a single cell genome analysis platform called Celinus for biomarker discovery. Through collaborations with clinicians and pharmaceutical companies, Celinus can unearth new druggable targets or diagnostic markers in tumor microenvironment cells.

For more information, please visit kr-geninus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005559/en/

See more here:
Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research - BioSpace

Posted in Gene Medicine | Comments Off on Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research – BioSpace

BNTC Stock Price Increased 190.28%: Why It Happened – Pulse 2.0

Posted: at 6:26 pm

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) a development-stage biotechnology company that focuses on the development of novel genetic medicines increased by 190.28% today as it went from a previous close of $3.19 to $9.26. The company shares were trading at over 80% pre-market today as well. Investors were responding to a Schedule 13G filing that showed Morgan Stanley now has 249,174 shares in the company, representing a 5.2% stake.

Last month, Benitec Biopharma had announced the successful results of the interim analysis of the BB-301 Pilot Dosing Study. And the proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference (RNAi) with classical AAV-based gene therapy.

And through the use of the ddRNAi platform Benitecs goal is to create genetic medicines that (following a single administration) will enable target tissues to perpetually produce siRNA molecules which facilitate the sustained silencing of disease-causing genes. The ddRNAi platform also allows for concomitant delivery of wild-type replacement genes and these distinct genetic elements work in concert to silence the expression of disease-causing mutant genes and to simultaneously replace the mutant genes with normal (wild type) genes to restore the natural underlying physiology of the diseased tissues.

BB-301, the most advanced genetic medicine currently under development by Benitec, employs the proprietary platform which allows for a Silence and Replace approach to the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). And BB-301 is a genetic medicine employing the Silence and Replace approach for the treatment of OPMD.

OPMD is known as a chronic life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. OPMD is caused by a mutation in the gene encoding poly(A) binding protein nuclear 1 (PABPN1). And patients with OPMD lose the ability to swallow liquids and solids, and the natural history of the disorder is characterized by chronic malnutrition, aspiration, and fatal episodes of aspiration pneumonia.

There are no therapeutic agents approved for the treatment of OPMD. Unfortunately, there is not any surgical interventions capable of altering the long-term natural history of OPMD are available. And BB-301 received Orphan Drug Designation in the United States and the European Union which provides commercial exclusivity (independent of intellectual property protection) and opportunities for efficient pathways for regulatory review and approval. While OPMD is a rare (Orphan) disorder, the commercial opportunity for a safe and efficacious therapeutic agent in this indication exceeds $1 billion over the course of the commercial life of the product.

Benitec had scheduled a Scientific Advice Meeting in France in May 2021 to review the interim data and the Phase 1 clinical trial design. And the company continues to plan for the initiation of the first-in-human clinical study of BB-301 in OPMD patients in 2022. The interim data validated the promise of the Silence and Replace approach to disease management and Benitec plans to provide additional pipeline updates in the second half of 2021.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Link:
BNTC Stock Price Increased 190.28%: Why It Happened - Pulse 2.0

Posted in Gene Medicine | Comments Off on BNTC Stock Price Increased 190.28%: Why It Happened – Pulse 2.0

BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened – Pulse 2.0

Posted: at 6:26 pm

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) a development-stage biotechnology company that focuses on the development of novel genetic medicines increased by over 80% pre-market. Investors are responding to a Schedule 13G filing showing that Morgan Stanley now has 249,174 shares in the company.

Last month, Benitec Biopharma had announced the successful results of the interim analysis of the BB-301 Pilot Dosing Study. The proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference (RNAi) with classical AAV-based gene therapy.

And through the use of the ddRNAi platform Benitecs goal is to create genetic medicines that, following a single administration, will enable target tissues to perpetually produce siRNA molecules which facilitate the sustained silencing of disease-causing genes. The ddRNAi platform also allows for concomitant delivery of wild-type replacement genes, and these distinct genetic elements work in concert to silence the expression of disease-causing mutant genes and to simultaneously replace the mutant genes with normal (wild type) genes to restore the natural underlying physiology of the diseased tissues.

And BB-301, the most advanced genetic medicine currently under development by Benitec, employs the proprietary platform which allows for a Silence and Replace approach to the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is a genetic medicine employing the Silence and Replace approach for the treatment of OPMD.

OPMD is known as a chronic life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. And OPMD is caused by a mutation in the gene encoding poly(A) binding protein nuclear 1 (PABPN1). Patients with OPMD lose the ability to swallow liquids and solids, and the natural history of the disorder is characterized by chronic malnutrition, aspiration, and fatal episodes of aspiration pneumonia.

There are no therapeutic agents approved for the treatment of OPMD. And there is not any surgical interventions capable of altering the long-term natural history of OPMD are available. BB-301 received Orphan Drug Designation in the United States and the European Union which provides commercial exclusivity (independent of intellectual property protection) and opportunities for efficient pathways for regulatory review and approval. While OPMD is a rare (Orphan) disorder, the commercial opportunity for a safe and efficacious therapeutic agent in this indication exceeds $1 billion over the course of the commercial life of the product.

Benitec had scheduled a Scientific Advice Meeting in France in May 2021 to review the interim data and the Phase 1 clinical trial design. And the company continues to plan for the initiation of the first-in-human clinical study of BB-301 in OPMD patients in 2022. The interim data validated the promise of the Silence and Replace approach to disease management and Benitec plans to provide additional pipeline updates in the second half of 2021.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Read the original here:
BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened - Pulse 2.0

Posted in Gene Medicine | Comments Off on BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened – Pulse 2.0

Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer -…

Posted: at 6:26 pm

The single-center, prospective, observational study evaluated molecular response in patients with mNSCLC (n=51) receiving pembrolizumab-based therapy, as monotherapy or with chemotherapy, as first- or second-line treatment. Changes in ctDNA were evaluated from baseline to nine weeks post-therapy initiation, and correlated with clinical and radiographic response.

In the study, the Guardant360 test showed that molecular responders achieved improved durable clinic benefit (log mean 49.4% vs. 3.5%) and significantly longer progression-free survival (median 14.1 vs. 4.4 months) and overall survival (median 22.1 vs. 12.0 months) compared to non-molecular responders. Molecular response was also associated with radiologic response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) .

Unfortunately, only a subset of patients with metastatic non-small cell lung cancer will respond to pembrolizumab-based therapy, and their failure to achieve clinical benefit becomes evident after their disease has progressed, said Helmy Eltoukhy, Guardant Health CEO. This study adds to the growing body of evidence showing that our Guardant360 test can effectively measure molecular response, giving clinicians an earlier indication whether to continue or stop treatment, explore other therapeutic regimens, or enroll the patient in a clinical trial.

The Guardant360 test is used to guide treatment in metastatic non-small cell lung cancer as the number of treatment-relevant genomic alterations continues to grow. Using next-generation sequencing, Guardant360 analyzes 83 genes using cell-free tumor DNA from blood samples. The Guardant360 test is broadly covered by Medicare for use across the vast majority of advanced solid tumors, including patients with metastatic non-small cell lung cancer. Last year, the FDA approved the Guardant360 CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor).

"These are exciting results that further support the value of liquid biopsies as a noninvasive tool to measure early treatment responses by evaluating molecular response or changes in circulating tumor DNA," said Charu Aggarwal, MD, MPH, Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penns Perelman School of Medicine and Abramson Cancer Center "We look forward to additional studies to help make this approach a reality in the clinical setting to personalize immunotherapy based treatment decisions for patients with metastatic non-small cell lung cancer."

The publication, titled Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy, can be found here: doi.org/10.1200/PO.20.00321.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential scope, impact or benefit of Guardant Health liquid biopsies which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Healths financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 as well as in its other reports filed with the Securities and Exchange Commission, including, when filed, its Quarterly Report on Form 10-Q for the period ended March 31, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Healths views as of any date subsequent to the date of this press release.

REFERENCES

1. Raja R, Kuziora M, Philip Z. Brohawn PZ, et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res; 2018: 24(24): 6212-6222. DOI: 10.1158/1078-0432.CCR-18-0386.

2. Aggarwal C,Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC. J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.

3. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med; 2018: 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z.

4. Shaw AT, Martini JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol; 2019: 37:15_suppl, 9019-9019. DOI: 10.1200/JCO.2019.37.15.

5. Pascual J, Cutts RJ, Kingston B, et al. Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-02.DOI: 10.1158/1538-7445.SABCS20-PS5-02.

6. Mack PC, Redman MW, Moon J, et al. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. J Clin Oncol; 2020: 38:15_suppl, 9532-9532. DOI: 10.1200/JCO.2020.38.15.

7. Maron SB, Chatila WK, Millang BM, et al, Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. J Clin Oncol; 2020: 38:15_suppl, 4559-4559. DOI: 10.1200/JCO.2020.38.15.

8. Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol; 2020: 38(17):1887-1896. DOI: 10.1200/JCO.19.02318.

9. Zhang Q, Luo J, Wu S, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov; 2020: 10:12, 1842-1853. DOI: 10.1158/2159-8290.CD-20-0047.

10. Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis; 2021: 5, 510-524. DOI: 10.1200/PO.20.00321.

Source: Guardant Health, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210326005031/en/

Read more from the original source:
Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer -...

Posted in Gene Medicine | Comments Off on Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer -…

Why Do We Age, and Can Anything Be Done to Stop or Slow it? – Healthline

Posted: at 6:26 pm

Aging refers to the physiological changes we experience during our lifespan. Its also an inevitable part of life.

After all, our cells arent made to last forever. The structures and functions in our cells decline over time.

But why does this happen? For decades, scientists have been studying the subject. There are currently more than 300 theories on why we age, and experts are learning more every day.

Lets explore why humans age, and how you can slow down the effects.

Aging can be categorized into two types:

Cellular aging is due to intrinsic factors. Its related to the biological aging of cells.

Cells are the basic building blocks of the body. Your cells are programmed to divide, multiply, and perform basic biological functions.

But the more cells divide, the older they get. In turn, cells eventually lose their ability to function properly.

Cellular damage also increases as cells get older. This makes the cell less healthy, causing biological processes to fail. Cellular damage accumulates over time, too.

Damage-related and environmental aging is related to extrinsic factors. It refers to how our surroundings and lifestyle affect how we age.

This includes factors like:

Over time, these factors can damage our cells and contribute to aging.

Everyone experiences both types of aging. However, each form of aging varies from person to person, which explains why we age in different ways.

Its generally accepted that aging is caused by multiple processes, rather than one reason. Its also likely that these processes interact and overlap with each other.

Here are some of the most prominent theories:

Programmed aging theories posit that were programmed, or designed, to age. It maintains that cells have a predetermined lifespan thats naturally encoded into the body.

Programmed theories are also called active or adaptive aging theories. These theories include:

Programmed theories have many supporters. However, they suggest that habits linked to longevity, like quitting smoking and exercise, are useless. This is likely inaccurate, as research has continuously proven that these habits affect life expectancy.

Error theories, or damage theories, are the opposite of programmed theories. They hypothesize that aging is caused by cellular changes that are random and unplanned.

Error theories of aging include:

The genetic theory proposes that aging primarily depends on genetics. In other words, our life expectancy is regulated by the genes we got from our parents.

Since genes have predetermined traits, its thought this theory overlaps with programmed theories of aging.

Genetic theories include:

The limitation of genetic theories is that they disregard the importance of external factors. In fact, its estimated that just 25 percent of lifespan is influenced by genetics. This suggests that environmental and lifestyle factors play a major role.

Natural selection refers to the adaptive traits of an organism. These traits can help the organism adjust to their environment, so theyre more likely to survive.

According to evolutionary theories, aging is based on natural selection. It posits that an organism begins aging after they have reached their peak of reproduction and have passed down adaptive traits.

Evolutionary theories include:

These theories are still being researched and require more evidence.

Another theory is that biochemical reactions cause aging. These reactions occur naturally and continuously throughout life.

This theory is rooted in various concepts, including:

In recent decades, life expectancy around the world has increased. This is due many factors, including:

These factors can protect our cells and reduce cellular damage, thus increasing life expectancy.

In most parts of the world, women live longer than men. This is due to several biological, social, and environmental factors.

Women, on average, have more estrogen than men. Estrogen is the female sex hormone. Its been found to have anti-inflammatory and immune-boosting effects, which may protect women from certain diseases.

In contrast, the male sex hormone testosterone may suppress the immune system. Men typically have more of this hormone.

There are also behavioral differences between men and women. Generally, compared to men, women:

Though aging is inevitable, its possible to slow down some of the effects. You can do this by following healthy lifestyle habits.

Heres how to slow aging:

Aging is likely caused by a combination of reasons. Some theories suggest cells have a predetermined lifespan, while others claim its caused by error and damage. Other theories posit that aging is due to genetic, evolution, or biochemical reactions.

Aging is normal, but following a healthy lifestyle can help you live longer. Habits like eating well, exercising regularly, and wearing sunscreen can reduce your risk of disease and improve your quality of life.

See the original post here:
Why Do We Age, and Can Anything Be Done to Stop or Slow it? - Healthline

Posted in Gene Medicine | Comments Off on Why Do We Age, and Can Anything Be Done to Stop or Slow it? – Healthline

Common skin problems in children and their prevention – BOSS Magazine

Posted: at 6:19 pm

Reading Time: 3 minutes

A considerable number of children face skin disorders daily. And some children grow up dealing with the same skin issues into their adulthood. As children are not cautious of their hygiene, they are more susceptible to skin problems that are rare in adults.

Diaper rash is relatively common among infants and toddlers. Similarly, chickenpox and measles are a part of every kids childhood. Usually, with age, most skin problems go away, but genetic conditions are lifelong and permanent. With a Health card, a parent can pay for the frequent hospital visits with ease.

For a parent, it is difficult to see your little bundle of joy in discomfort. Sometimes, skin disorders can indicate an underlying disease as well. Most common skin disorders in childhood include eczema, diaper rash, acne, ringworm, rashes from bacterial infection, etc. Nowadays, pollution and the demand for junk food have increased the chances of lifestyle diseases among children that directly affect their skin. Therefore, it is advisable to consult a dermatologist early on. For instance, a dermatologist in Delhi is always in demand to treat acne flares due to seasonal allergies. Here are some skin problems that happen in children and can be treated with a professionals help.

Diaper rash is usual among babies and is characterized by bright red skin in the diaper region. It happens due to chafing and skin sensitivity due to wet, tight, or infrequently changed diapers. Even if a baby wears a diaper daily, then chances are high of getting a diaper rash. The baby can get extremely irritable and restless, which can be annoying and tiring. Simple home treatments such as applying ointments, air drying, and changing diapers on time are quite useful. If you do not see any improvement in the babys skin, then it is time to see a doctor.

According to a study, every one in ten children suffers from eczema. Thus, it is the most common rash among children. Eczema makes the skin more sensitive and causes red, dry, and itchy skin. Mostly, the environment and heredity are to blame for eczema. Allergic conditions such as asthma and allergic rhinitis cause eczema as well. Every kid can experience different types of eczema rashes. In babies, it usually happens on the scalp and face. It occurs in elbow creases in young children, on the neck, around the eyes, and back of the knee. A misconception with eczema is that it is contagious, which is far from the truth.

Psoriasis causes dry patches on the skin that are incredibly itchy. A study shows that 40% of people experience psoriasis as early as ten years of age. Psoriasis can vary from mild to severe in children. Usually, the cases are mild and can get better with an effective treatment. It has no cure and is lifelong, but medication helps in keeping the condition manageable. Just like eczema, psoriasis is not contagious. The main factor behind psoriasis is a bacterial infection. Certain medications, cold weather, or stress are the most significant contributors to psoriasis among children.

Human papillomavirus causes warts and can cause different kinds similar to its nature. Mostly, these are harmless skin growths, but they can also be painful and irritating. Children have warts more than an adult. If your kid has a weak immune system or a contact with a person having warts, they are more likely to have it. A dermatologist will do a physical test and scrape a small amount for biopsy to ascertain what kind of wart is there. Warts fade away in weeks with gentle care and can be treated with over-the-counter products. Severe cases will require medication and other procedures for treating warts.

It is a viral disease that induces a small, pink colored bump on your childs skin. Molluscum is not harmful, with no other severe symptoms. The bumps contain the virus, which is mildly contagious. A virus known as poxvirus causes molluscum. Children can contract it by coming into contact, skin-to-skin, with a molluscum patient. Also, hot, humid areas are a trigger for worsening molluscum. Even though the bumps are small in size but can cause significant discomfort to the child, a dermatologist will diagnose molluscum by just taking a glance at it. In fact, with a Bajaj Health, one can find a network hospital for a regular visit for molluscum removal.

Skin conditions may not seem severe or acute but can indicate your internal well-being. A child becomes more self-conscious in situations wherein they can be made to feel inferior or left out. It is best to see a dermatologist as soon as possible if your child faces any skin discomfort. Treatment and medication for skin disorders have always been high. In cases where long-term treatment is required, a Bajaj Health EMI card can prove to be useful and convenient. So, never ignore any little signs that may show any kind of skin problem.

Read this article:
Common skin problems in children and their prevention - BOSS Magazine

Posted in Eczema | Comments Off on Common skin problems in children and their prevention – BOSS Magazine

Mildly Alkaline Cream Reduces Eczema-Related Skin Inflammation in Patients With Atopic Dermatitis – Dermatology Advisor

Posted: at 6:19 pm

Local treatment with topical creams featuring a mild alkaline pH could be helpful in reducing eczema-related skin inflammation in patients with mild atopic dermatitis (AD), a study published in the Journal of Cosmetic Dermatology suggests.

The single-arm, open-label study enrolled 25 patients (median age, 22.5 years) with mild AD and eczema who were not using topical or systemic glucocorticoids and/or antihistamines. Treatment consisted of Alkaline Build Up Caring Cream INTENSIVE and Alkaline Build Up Caring Cream PLUS+ (Siriderma) for 8 weeks. The patented INTENSIVE cream product contains 25% zinc oxide and 1% sulfur and are combined in a mild alkaline environment with high levels of multiunsaturated fatty acids. Likewise, the AC PLUS+ product contains small amounts of both zinc oxide and colloidal silver.

At baseline and at 8 weeks, patients underwent dermatological, biochemical, and questionnaire-based examinations. Intensity and extension of AD were assessed using the objective SCORAD index, skin pH was measured using a skin planar glass electrode pH meter, and blood samples were taken to examine inflammatory markers.

At baseline, the mean pH on the skin surface was 5.96. There was a small and insignificant 3.8% increase in pH after 8 weeks of treatment with the alkaline creams (P =.15). The researchers noted that this finding was important, given the role of pH in maintaining the outermost skin barrier function as well as the skin microbiome.

At 8 weeks, there was an approximately 30% decrease in total eczematous-affected skin area (P =.025). There were also significant reductions in average severity scores for erythema (P <.001), desquamation (P <.001), and lichenification (P <.001) by 8 weeks. In addition, there was a small increase in interleukin-8 by 8 weeks (7.48 vs 8.52 pg/mL; P =.037).

Patients also reported a 62.8% decrease in itching (P <.001), a 68.1% decrease in redness (P <.001), a 59.6% decrease in skin dryness (P <.001), and a 66.7% decrease in skin cracking (P =.002) by the end of treatment.

Limitations of this study included its lack of a control arm, the small sample size, and its open-label design.

The investigators concluded that this topical local therapy alone or in combination with other anti-inflammatory drugs might represent an interesting and beneficial option for this diagnosis for which, to date, no curative treatment is available.

Jurecek L, Rajcigelova T, Kozarova A, et al. Beneficial effects of an alkaline topical treatment in patients with mild atopic dermatitis. J Cosmet Dermatol. doi:10.1111/jocd.13936

Originally posted here:
Mildly Alkaline Cream Reduces Eczema-Related Skin Inflammation in Patients With Atopic Dermatitis - Dermatology Advisor

Posted in Eczema | Comments Off on Mildly Alkaline Cream Reduces Eczema-Related Skin Inflammation in Patients With Atopic Dermatitis – Dermatology Advisor

Baby Allergic Reaction to Food: Signs and Symptoms – Healthline

Posted: at 6:19 pm

Introducing your baby to solid foods can be such a fun and exciting time. But if you suspect your little one may have allergies, you might be worried about potential reactions and for good reason!

Food allergies affect up to 8 percent of children in the United States.

While a family history of food allergies and similar conditions may be a clue that your baby will have allergies as well, its not always the best predictor.

Heres how to get familiar with what a reaction looks like, learn how to spot a severe reaction, and understand the steps youll need to take to get your baby help.

Anaphylaxis is a severe allergic reaction that can be life threatening. If you suspect your baby may be having a serious reaction, call 911 or head to the nearest emergency room.

Symptoms may include:

Researchers share that babies tend to have hives, wheezing, and vomiting more than other symptoms.

One of the features of anaphylaxis versus a mild reaction is that it may come on quickly think 5 to 30 minutes after exposure. Recognizing these signs in your baby is the most important step to getting help.

So, what exactly is an allergic reaction? Well, if your baby is exposed to a substance like a food or beverage that theyre allergic to, a reaction is their bodys way of defending itself.

When exposed to an allergen, the body releases histamines that cause inflammation. As a result, your baby may have anything from mild to moderate or even severe symptoms.

Mild or moderate allergic reactions can happen after your baby touches, swallows, tastes, eats, or breathes in something theyre allergic to.

Symptoms might include:

Even exposure to a tiny amount of a food theyre allergic to, like a piece of a peanut, can be enough to produce a reaction in some babies.

Of course, babies drool, spit up, and cry relatively often. They also dont have the verbal skills to tell you something is wrong. Your baby may try to communicate that theyre not feeling well in some other way.

Pay close attention to your baby to spot these other possible signs of reaction:

Again, one of the key features of a severe reaction versus a mild one is that it comes on soon after exposure.

Signs of anaphylaxis in babies tend to be milder than in older children and adults. The most reported symptoms of severe allergic reaction in babies are hives and vomiting.

In a 2018 study on 357 children ranging from infants to school-aged kids, researchers discovered that babies who have allergic reactions tend to have stomach issues 89 percent of the time.

Specifically, vomiting was present in 83 percent of severe reactions to foods. And a whopping 94 percent of babies experienced hives as part of their severe reaction versus just 62 percent of school-aged kids.

Only 17 percent of infants had breathing difficulties. In fact, just a single baby had wheezing.

And only one baby had low blood pressure as a result of their severe reaction, which is a hallmark sign of anaphylaxis in older children and adults.

That all said, its important to be able to identify any allergy signs in your little one, especially soon after consuming certain foods.

If your child has any of these signs, dont hesitate to call 911 and get help. Even if you arent sure, its better to be safe than sorry.

Depending on the severity of the reaction, youll want to act fast to get your baby help especially if this is their first reaction.

In particular, youll want to get emergency help (call 911) if your baby has:

Combinations of other symptoms are also important to spot, like rash or swelling along with loose stools and vomiting.

If youve dealt with reactions before, your doctor likely prescribed an epinephrine pen (EpiPen) to use in cases of severe reactions.

Use this drug as directed, then call an ambulance or drive to the ER. Either way, be ready to do CPR if your baby stops breathing at any time.

Once medical staff arrive, let them know that youve administered epinephrine. You may need to give another dose of the drug if symptoms return.

If your baby does have a severe reaction, its important to keep an eye on them for 6 to 8 hours after treatment. Thats because theres risk of rebound anaphylaxis (severe symptoms that recur), typically within 8 hours of the initial reaction in up to 20 percent of cases.

If your little one has a mild reaction, its a good idea to call and check in with their pediatrician.

They can tell you if there are any steps you should take or if your baby needs an appointment. The doctor may also order allergy testing so you can identify other possible allergens to avoid.

Related: What to expect when your baby has allergies

Most severe allergic reactions to foods will happen very soon after exposure. However, some milder reactions may take up to a few hours (usually around 2 hours) to become apparent.

Food allergies may be more common in families with a history of allergies and associated conditions, like asthma, eczema, or even hay fever.

The great majority of food-related allergic reactions are caused by one of the following:

Of all foods, babies are most likely to be allergic to:

Though less common, some babies may be allergic to:

Babies and children can outgrow their allergies over time, though allergies to peanuts, tree nuts, fish, and shellfish may be lifelong.

Experts recommend exposing babies to high-risk foods before they reach their first birthdays. Research from 2015 supports the idea that earlier exposure to peanuts, for example, may lower the risk of developing a peanut allergy later on.

So, for example, youll want to cook eggs and prepare peanuts in age-appropriate ways (fully cooked eggs, smooth peanut butter) and offer them up to twice per week.

How to do it:

If you have a family history of food allergies, speak with your doctor about early introduction to certain foods. Some pediatricians may suggest you give the food under medical supervision in case of a severe reaction.

Related: How to safely introduce your baby to peanuts and other food allergens

The tricky thing with food allergies is that your babys reaction may not always be the same severity. Allergy experts explain that food that causes a relatively mild reaction one time may cause a more severe reaction another time.

Unfortunately, theres no specific drug or supplement you can take to prevent or treat food allergies as a whole.

Instead, the goal is to avoid foods that cause reaction and have emergency treatment available in the event that baby has been exposed.

Some tips for avoiding allergenic foods:

Theres no current evidence to support a restrictive diet while breastfeeding to prevent allergies in babies. Instead, work with a doctor for guidance on dietary changes only after your baby shows a potential reaction to a food.

The proteins from food reach breast milk approximately 3 to 6 hours after consumption. After eliminating allergenic foods, it may take between 1 and 2 weeks for your babys allergy symptoms to subside.

Speak with your babys pediatrician if you have any concerns about giving allergenic foods to your child. Your doctor should have the most up-to-date information about how to prepare and introduce these foods in the safest way possible.

Your childs doctor can also help you get appropriate allergy testing if needed and develop a plan for cases of severe reaction so youll feel more confident in an emergency.

Follow this link:
Baby Allergic Reaction to Food: Signs and Symptoms - Healthline

Posted in Eczema | Comments Off on Baby Allergic Reaction to Food: Signs and Symptoms – Healthline

Itchy Bum at Night: Causes, Treatments, When to See a Doctor – Healthline

Posted: at 6:19 pm

We all know how elusive the perfect night of sleep can be. From a room thats too hot to the millions of thoughts that might be running through your mind, theres no shortage of potential interruptions. Thats why its important for us to determine which annoyances we can control. If you find yourself kept up at night by an irritating itch around your backside, you are not alone.

There are steps you can take to identify the cause of any nighttime itching you may notice around your bum. Whether these symptoms are more noticeable at night, or specific to nighttime, there are plenty of ways to treat this discomfort.

Itching may be more common at night due to activities that typically precede sleep: dinner, drinking, use of the toilet, and showering, for example. Additionally, we may become more sensitive to irritants at night since there is less stimulus to distract us than throughout the rest of the day.

So what could be the root of your nighttime itch?

Be sure to wipe correctly following the use of the toilet. You may notice that wiping too hard can cause irritation and over-dry the area around the anus. Alternatively, wiping too gently can leave some fecal residue, which might contribute to additional irritation and the potential for infection in any areas where the skin might be chapped or broken.

For the most success in the bathroom, consider using two-ply toilet paper and wiping gently from front to back. You also might also find a bidet useful, as water pressure can produce a better clean.

If you find that your anal area is itching at night, its possible that you might be experiencing hemorrhoids or anal fissures. These are preexisting conditions that may cause itch and could be exacerbated by nighttime use of the toilet, diet, or nighttime sweating.

A number of foods can irritate the anus and produce an itch. This includes, but is not limited, to:

If youre experiencing an itchy anus, consider temporarily cutting the above food and drink from your diet for 48 hours to see if you notice a difference.

In general, sweat can irritate the skin because it contributes to heat retention and dryness of the skin.

Itchiness at night can be more prevalent because of night sweats. Combatting the cause of night sweats can relieve itching around the bum and anus.

Some tips include:

A side effect of some medications can be itchiness. Read and understand the side effects of any medication youre taking.

Examples of medications that may contribute to nighttime anal itching are blood pressure medications and antibiotics. When antibiotics kill the good bacteria in your gut, you may experience diarrhea. Diarrhea may worsen the symptoms of anal itching

Fabrics that are tight and restrictive can cause irritation. Try wearing 100 percent cotton, loose underwear to combat itching around your bum at night.

Threadworms (pinworms) are parasitic worms that infect human digestive systems. They cause the most itchiness at night when females are laying their eggs around the anus. Threadworms are able to survive on clothing and bed sheets, which provides the opportunity to transfer the worms from one person to another.

They are most common in children and can be detected by doing a stool sample. Threadworms can be treated with medication and a routine of strict hygiene measures.

Many people experience skin diseases on their bodies. This includes your buttocks and anus, which are not exempt from psoriasis, eczema, and others.

Consider seeing a dermatologist to rule out skin diseases like psoriasis and eczema if you have the following symptoms around your anus:

When menstruating, its considered safest to sleep with a menstrual pad. The added moisture from menstruating at night can contribute to increased itch and irritation around the anus, vagina, and buttocks.

Throughout the day, remember to change your pads every 4 hours and to keep your underwear fresh. At nighttime, opt for extra-absorbent pads or menstrual cups to keep added moisture or discomfort at bay.

Yeast infections may occur in and near the vagina, penis, or anus, and may contribute to nighttime itching.

Additionally, common symptoms of several sexually transmitted diseases (STDs) may include itching of the vagina, penis, and anus. If youre sexually active, participate in regular STD testing.

Nighttime sex can also be a contributor to vaginal itchiness at night. If you are noticing extra itchiness after intercourse, consider the following tips:

Children can be particularly susceptible to experiencing itchiness around their bottoms at night. The following items are likely causes:

While there are several possible causes for an itchy bum at night, most symptoms can be relieved with the following tips.

For immediate relief, the use of ointments or gels can be an effective way to minimize nighttime anal itching.

Wearing breathable underwear at night is important for maintaining comfort.

Try combating night sweats by avoiding alcohol before bed, keeping your bedroom cool, and using breathable sheets.

Being intentional about your hygiene can both improve and solve symptoms of nighttime itching around the anus:

A variety of foods and drinks can contribute to anal itching. Consider eliminating spicy food, coffee, and alcohol from your diet temporarily to improve the symptoms of anal itching at night.

While a lot of symptoms of an itchy bum at night are mild, see a doctor if:

A doctor will be able to help you determine the cause and improve your symptoms.

Bum itchiness can be aggravating when youre trying to sleep peacefully. You should start seeing improvements in your symptoms by making changes in your day-to-day routine.

By being mindful of your hygienic practices, diet, and sleep environment, you should be able to determine the cause of your nighttime itching. If your nighttime itching persists or worsens, schedule a visit with a doctor for additional advice.

See the article here:
Itchy Bum at Night: Causes, Treatments, When to See a Doctor - Healthline

Posted in Eczema | Comments Off on Itchy Bum at Night: Causes, Treatments, When to See a Doctor – Healthline

Devonian Health Group Provides More Details on Previously Announced Positive Topline Results From Phase 2 Clinical Trial of Thykamine in Adult…

Posted: at 6:19 pm

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (Devonian or the Corporation) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, provides further details on previously announced results of Thykamine Phase 2 clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).

In this 4-week, phase 2, randomized, double-blind, multicentre, placebo-controlled study, adult patients with mild-to-moderate AD were randomized to receive Thykamine cream 0.05%, 0.10%, 0.25% or vehicle cream (placebo) twice daily. The primary efficacy endpoint was the Investigator Global Assessment (IGA) success rate defined as percentage of patients with an IGA score of 0 or 1 with greater than or equal to 2-grade reduction at week 4. Secondary endpoints included Body Surface Area (BSA) and Eczema Area and Severity Index (EASI). A total of 162 patients, spread over several sites in Canada, were recruited for this study.

IGA success rates at week 4 were 6.7% for placebo (vehicle cream), 19.0% for Thykamine cream 0.05% (p=0.053 vs placebo), 30.8% Thykamine cream 0.10% (p=0.014 vs placebo) and 12.1% for Thykamine cream 0.25% (p=0.461 vs placebo). Success rate over placebo of Thykamine cream 0.1% was not only reached at week 4 but also at week 3 (p = 0.04), resulting in a fast onset of the therapeutic effect. As such, Thykamine cream 0.10% has been retained for Phase 3 trials.

In addition, Thykamine achieved statistically significant differences, compared to placebo, in its key secondary efficacy endpoint, i.e. BSA.

Lastly, Thykamine was well-tolerated, as very few adverse events were reported.

"The efficacy of Thykamine obtained in this clinical trial was as expected and compared favourably to published results of other therapeutic products such as the phosphodiesterase inhibitors (PDE4)1,2 and calcineurin inhibitors,3 demonstrating that a Botanical Drug candidate can be as potent as a product derived from chemical synthesis." said Dr Andr P. Boulet, President and CEO of Devonian. "With the successful completion of this dose ranging study, we can now move into phase 3 clinical development in the adult patients. We are also planning a clinical trial within the pediatric patient population" added Dr Boulet.

Grant of Stock Options

In addition, the Company announces that the Board of Directors has approved the grant of 60,000 stock options (the "Options") to a member of the Board of Directors. These options are exercisable on the grant date, at a price of $ 0.20, for a period of 10 years.

About Atopic Dermatitis (AD)

AD, also known as eczema, is a type of inflammation of the skin. It results in itchy, red, swollen, and cracked skin that may lead to secondary infection. The condition typically starts in childhood with changing severity over the years. Although the cause of AD is unknown, it is believed to involve genetics, a compromised immune system and can be triggered by environmental factors. AD is the most common skin disease4 and its prevalence continues to increase worldwide. In the United States, the incidence has been reported to be 10-20% of children with new diagnoses at almost 11% per year5. The severity of AD can be categorized into three stages, mild, moderate, and severe. The mild and moderate forms constitute approximately 67% and 26% respectively of the AD childhood patient population. A similar distribution has been reported in the adult patient population (71% and 26% respectively) 6,7. There is currently an enormous unmet need for new, effective, and well-tolerated treatment options in AD8.

About Thykamine

Thykamine, the first pharmaceutical product issued from Devonians SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis. Thykamine is currently under development as treatment for ulcerative colitis and atopic dermatitis. Both Thykamine and SUPREX platform are protected by several patents in North America, Europe and Asia.

About Devonian

Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonians focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Qubec, Canada where it owns a state-of-the art extraction facility with full traceability from the seed to the pill. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).

For more information, visit http://www.groupedevonian.com

References

Forward Looking Statements

This press release contains forward-looking statements about Devonians objectives, strategies and businesses that involve risks and uncertainties. These statements are forward-looking because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonians ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonians prospectus dated April 21st, 2017 under the heading Risk Factors related to Devonians business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Read the original post:
Devonian Health Group Provides More Details on Previously Announced Positive Topline Results From Phase 2 Clinical Trial of Thykamine in Adult...

Posted in Eczema | Comments Off on Devonian Health Group Provides More Details on Previously Announced Positive Topline Results From Phase 2 Clinical Trial of Thykamine in Adult…

Page 1,022«..1020..1,0211,0221,0231,024..1,0301,040..»